APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Live Attenuated Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Live Attenuated Vaccines Market Analysis and Forecast 2026-2032

Report ID 174008390220 December 2025198 pages

Choose your research edition.

Industry ResearchLive Attenuated Vaccines Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Live Attenuated Vaccines Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal Live Attenuated Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Live Attenuated Vaccines Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Live Attenuated Vaccines Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Live Attenuated Vaccines market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Live Attenuated Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Live Attenuated Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Live Attenuated Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Live Attenuated Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Live Attenuated Vaccines include Astellas Pharma, CSL, Serum Institute Of India, GlaxoSmithKline, Pfizer, Merck, Johnson & Johnson and Sanofi, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Live Attenuated Vaccines, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Live Attenuated Vaccines, also provides the sales of main regions and countries. Of the upcoming market potential for Live Attenuated Vaccines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Live Attenuated Vaccines sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Live Attenuated Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Live Attenuated Vaccines sales, projected growth trends, production technology, application and end-user industry.

Live Attenuated Vaccines Segment by Company

Astellas Pharma

CSL

Serum Institute Of India

GlaxoSmithKline

Pfizer

Merck

Johnson & Johnson

Sanofi

Live Attenuated Vaccines Segment by Type

Bacterial

Viral

Live Attenuated Vaccines Segment by Application

Research Institutes

Hospitals

Clinics

Others

Live Attenuated Vaccines Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Live Attenuated Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Live Attenuated Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Live Attenuated Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Live Attenuated Vaccines in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Live Attenuated Vaccines manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Live Attenuated Vaccines sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Live Attenuated Vaccines Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Bacterial Major Manufacturers Table 3. Viral Major Manufacturers Table 4. Global Live Attenuated Vaccines Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Research Institutes Major Manufacturers Table 6. Hospitals Major Manufacturers Table 7. Clinics Major Manufacturers Table 8. Others Major Manufacturers Table 9. Live Attenuated Vaccines Industry Trends Table 10. Live Attenuated Vaccines Industry Drivers Table 11. Live Attenuated Vaccines Industry Opportunities and Challenges Table 12. Live Attenuated Vaccines Industry Restraints Table 13. Global Live Attenuated Vaccines Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 14. Global Live Attenuated Vaccines Revenue by Region (2021-2026) & (US$ Million) Table 15. Global Live Attenuated Vaccines Revenue by Region (2027-2032) & (US$ Million) Table 16. Global Live Attenuated Vaccines Revenue Market Share by Region (2021-2026) Table 17. Global Live Attenuated Vaccines Revenue Market Share by Region (2027-2032) Table 18. Global Live Attenuated Vaccines Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 19. Global Live Attenuated Vaccines Sales by Region (2021-2026) & (K Units) Table 20. Global Live Attenuated Vaccines Sales by Region (2027-2032) & (K Units) Table 21. Global Live Attenuated Vaccines Sales Market Share by Region (2021-2026) Table 22. Global Live Attenuated Vaccines Sales Market Share by Region (2027-2032) Table 23. Global Live Attenuated Vaccines Revenue by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Live Attenuated Vaccines Revenue Market Share by Manufacturers (2021-2026) Table 25. Global Live Attenuated Vaccines Sales by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Live Attenuated Vaccines Sales Market Share by Manufacturers (2021-2026) Table 27. Global Live Attenuated Vaccines Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 28. Global Live Attenuated Vaccines Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 29. Global Live Attenuated Vaccines Key Manufacturers Manufacturing Sites & Headquarters Table 30. Global Live Attenuated Vaccines Manufacturers, Product Type & Application Table 31. Global Live Attenuated Vaccines Manufacturers' Establishment Date Table 32. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 33. Global Live Attenuated Vaccines by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 34. Global Live Attenuated Vaccines Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Live Attenuated Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 36. Global Live Attenuated Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 37. Global Live Attenuated Vaccines Revenue Market Share by Type (2021-2026) Table 38. Global Live Attenuated Vaccines Revenue Market Share by Type (2027-2032) Table 39. Global Live Attenuated Vaccines Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 40. Global Live Attenuated Vaccines Sales by Type (2021-2026) & (K Units) Table 41. Global Live Attenuated Vaccines Sales by Type (2027-2032) & (K Units) Table 42. Global Live Attenuated Vaccines Sales Market Share by Type (2021-2026) Table 43. Global Live Attenuated Vaccines Sales Market Share by Type (2027-2032) Table 44. Global Live Attenuated Vaccines Price by Type (2021-2026) & (US$/Unit) Table 45. Global Live Attenuated Vaccines Price by Type (2027-2032) & (US$/Unit) Table 46. Global Live Attenuated Vaccines Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Live Attenuated Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 48. Global Live Attenuated Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 49. Global Live Attenuated Vaccines Revenue Market Share by Application (2021-2026) Table 50. Global Live Attenuated Vaccines Revenue Market Share by Application (2027-2032) Table 51. Global Live Attenuated Vaccines Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 52. Global Live Attenuated Vaccines Sales by Application (2021-2026) & (K Units) Table 53. Global Live Attenuated Vaccines Sales by Application (2027-2032) & (K Units) Table 54. Global Live Attenuated Vaccines Sales Market Share by Application (2021-2026) Table 55. Global Live Attenuated Vaccines Sales Market Share by Application (2027-2032) Table 56. Global Live Attenuated Vaccines Price by Application (2021-2026) & (US$/Unit) Table 57. Global Live Attenuated Vaccines Price by Application (2027-2032) & (US$/Unit) Table 58. Astellas Pharma Company Information Table 59. Astellas Pharma Business Overview Table 60. Astellas Pharma Live Attenuated Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Astellas Pharma Live Attenuated Vaccines Product Portfolio Table 62. Astellas Pharma Recent Development Table 63. CSL Company Information Table 64. CSL Business Overview Table 65. CSL Live Attenuated Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. CSL Live Attenuated Vaccines Product Portfolio Table 67. CSL Recent Development Table 68. Serum Institute Of India Company Information Table 69. Serum Institute Of India Business Overview Table 70. Serum Institute Of India Live Attenuated Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Serum Institute Of India Live Attenuated Vaccines Product Portfolio Table 72. Serum Institute Of India Recent Development Table 73. GlaxoSmithKline Company Information Table 74. GlaxoSmithKline Business Overview Table 75. GlaxoSmithKline Live Attenuated Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. GlaxoSmithKline Live Attenuated Vaccines Product Portfolio Table 77. GlaxoSmithKline Recent Development Table 78. Pfizer Company Information Table 79. Pfizer Business Overview Table 80. Pfizer Live Attenuated Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Pfizer Live Attenuated Vaccines Product Portfolio Table 82. Pfizer Recent Development Table 83. Merck Company Information Table 84. Merck Business Overview Table 85. Merck Live Attenuated Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Merck Live Attenuated Vaccines Product Portfolio Table 87. Merck Recent Development Table 88. Johnson & Johnson Company Information Table 89. Johnson & Johnson Business Overview Table 90. Johnson & Johnson Live Attenuated Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Johnson & Johnson Live Attenuated Vaccines Product Portfolio Table 92. Johnson & Johnson Recent Development Table 93. Sanofi Company Information Table 94. Sanofi Business Overview Table 95. Sanofi Live Attenuated Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Sanofi Live Attenuated Vaccines Product Portfolio Table 97. Sanofi Recent Development Table 98. North America Live Attenuated Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 99. North America Live Attenuated Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 100. North America Live Attenuated Vaccines Sales by Type (2021-2026) & (K Units) Table 101. North America Live Attenuated Vaccines Sales by Type (2027-2032) & (K Units) Table 102. North America Live Attenuated Vaccines Sales Price by Type (2021-2026) & (US$/Unit) Table 103. North America Live Attenuated Vaccines Sales Price by Type (2027-2032) & (US$/Unit) Table 104. North America Live Attenuated Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 105. North America Live Attenuated Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 106. North America Live Attenuated Vaccines Sales by Application (2021-2026) & (K Units) Table 107. North America Live Attenuated Vaccines Sales by Application (2027-2032) & (K Units) Table 108. North America Live Attenuated Vaccines Sales Price by Application (2021-2026) & (US$/Unit) Table 109. North America Live Attenuated Vaccines Sales Price by Application (2027-2032) & (US$/Unit) Table 110. North America Live Attenuated Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 111. North America Live Attenuated Vaccines Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 112. North America Live Attenuated Vaccines Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 113. North America Live Attenuated Vaccines Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 114. North America Live Attenuated Vaccines Sales by Country (2021-2026) & (K Units) Table 115. North America Live Attenuated Vaccines Sales by Country (2027-2032) & (K Units) Table 116. North America Live Attenuated Vaccines Sales Price by Country (2021-2026) & (US$/Unit) Table 117. North America Live Attenuated Vaccines Sales Price by Country (2027-2032) & (US$/Unit) Table 118. United States Live Attenuated Vaccines Revenue (2021-2032) & (US$ Million) Table 119. Canada Live Attenuated Vaccines Revenue (2021-2032) & (US$ Million) Table 120. Europe Live Attenuated Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 121. Europe Live Attenuated Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 122. Europe Live Attenuated Vaccines Sales by Type (2021-2026) & (K Units) Table 123. Europe Live Attenuated Vaccines Sales by Type (2027-2032) & (K Units) Table 124. Europe Live Attenuated Vaccines Sales Price by Type (2021-2026) & (US$/Unit) Table 125. Europe Live Attenuated Vaccines Sales Price by Type (2027-2032) & (US$/Unit) Table 126. Europe Live Attenuated Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 127. Europe Live Attenuated Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 128. Europe Live Attenuated Vaccines Sales by Application (2021-2026) & (K Units) Table 129. Europe Live Attenuated Vaccines Sales by Application (2027-2032) & (K Units) Table 130. Europe Live Attenuated Vaccines Sales Price by Application (2021-2026) & (US$/Unit) Table 131. Europe Live Attenuated Vaccines Sales Price by Application (2027-2032) & (US$/Unit) Table 132. Europe Live Attenuated Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 133. Europe Live Attenuated Vaccines Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 134. Europe Live Attenuated Vaccines Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 135. Europe Live Attenuated Vaccines Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 136. Europe Live Attenuated Vaccines Sales by Country (2021-2026) & (K Units) Table 137. Europe Live Attenuated Vaccines Sales by Country (2027-2032) & (K Units) Table 138. Europe Live Attenuated Vaccines Sales Price by Country (2021-2026) & (US$/Unit) Table 139. Europe Live Attenuated Vaccines Sales Price by Country (2027-2032) & (US$/Unit) Table 140. Germany Live Attenuated Vaccines Revenue (2021-2032) & (US$ Million) Table 141. France Live Attenuated Vaccines Revenue (2021-2032) & (US$ Million) Table 142. U.K. Live Attenuated Vaccines Revenue (2021-2032) & (US$ Million) Table 143. Italy Live Attenuated Vaccines Revenue (2021-2032) & (US$ Million) Table 144. Netherlands Live Attenuated Vaccines Revenue (2021-2032) & (US$ Million) Table 145. Nordic Countries Live Attenuated Vaccines Revenue (2021-2032) & (US$ Million) Table 146. China Live Attenuated Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 147. China Live Attenuated Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 148. China Live Attenuated Vaccines Sales by Type (2021-2026) & (K Units) Table 149. China Live Attenuated Vaccines Sales by Type (2027-2032) & (K Units) Table 150. China Live Attenuated Vaccines Sales Price by Type (2021-2026) & (US$/Unit) Table 151. China Live Attenuated Vaccines Sales Price by Type (2027-2032) & (US$/Unit) Table 152. China Live Attenuated Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 153. China Live Attenuated Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 154. China Live Attenuated Vaccines Sales by Application (2021-2026) & (K Units) Table 155. China Live Attenuated Vaccines Sales by Application (2027-2032) & (K Units) Table 156. China Live Attenuated Vaccines Sales Price by Application (2021-2026) & (US$/Unit) Table 157. China Live Attenuated Vaccines Sales Price by Application (2027-2032) & (US$/Unit) Table 158. Asia Live Attenuated Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 159. Asia Live Attenuated Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 160. Asia Live Attenuated Vaccines Sales by Type (2021-2026) & (K Units) Table 161. Asia Live Attenuated Vaccines Sales by Type (2027-2032) & (K Units) Table 162. Asia Live Attenuated Vaccines Sales Price by Type (2021-2026) & (US$/Unit) Table 163. Asia Live Attenuated Vaccines Sales Price by Type (2027-2032) & (US$/Unit) Table 164. Asia Live Attenuated Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 165. Asia Live Attenuated Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 166. Asia Live Attenuated Vaccines Sales by Application (2021-2026) & (K Units) Table 167. Asia Live Attenuated Vaccines Sales by Application (2027-2032) & (K Units) Table 168. Asia Live Attenuated Vaccines Sales Price by Application (2021-2026) & (US$/Unit) Table 169. Asia Live Attenuated Vaccines Sales Price by Application (2027-2032) & (US$/Unit) Table 170. Asia Live Attenuated Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 171. Asia Live Attenuated Vaccines Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 172. Asia Live Attenuated Vaccines Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 173. Asia Live Attenuated Vaccines Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 174. Asia Live Attenuated Vaccines Sales by Country (2021-2026) & (K Units) Table 175. Asia Live Attenuated Vaccines Sales by Country (2027-2032) & (K Units) Table 176. Asia Live Attenuated Vaccines Sales Price by Country (2021-2026) & (US$/Unit) Table 177. Asia Live Attenuated Vaccines Sales Price by Country (2027-2032) & (US$/Unit) Table 178. Japan Live Attenuated Vaccines Revenue (2021-2032) & (US$ Million) Table 179. South Korea Live Attenuated Vaccines Revenue (2021-2032) & (US$ Million) Table 180. India Live Attenuated Vaccines Revenue (2021-2032) & (US$ Million) Table 181. Australia Live Attenuated Vaccines Revenue (2021-2032) & (US$ Million) Table 182. China Taiwan Live Attenuated Vaccines Revenue (2021-2032) & (US$ Million) Table 183. Southeast Asia Live Attenuated Vaccines Revenue (2021-2032) & (US$ Million) Table 184. SAMEA Live Attenuated Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 185. SAMEA Live Attenuated Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 186. SAMEA Live Attenuated Vaccines Sales by Type (2021-2026) & (K Units) Table 187. SAMEA Live Attenuated Vaccines Sales by Type (2027-2032) & (K Units) Table 188. SAMEA Live Attenuated Vaccines Sales Price by Type (2021-2026) & (US$/Unit) Table 189. SAMEA Live Attenuated Vaccines Sales Price by Type (2027-2032) & (US$/Unit) Table 190. SAMEA Live Attenuated Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 191. SAMEA Live Attenuated Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 192. SAMEA Live Attenuated Vaccines Sales by Application (2021-2026) & (K Units) Table 193. SAMEA Live Attenuated Vaccines Sales by Application (2027-2032) & (K Units) Table 194. SAMEA Live Attenuated Vaccines Sales Price by Application (2021-2026) & (US$/Unit) Table 195. SAMEA Live Attenuated Vaccines Sales Price by Application (2027-2032) & (US$/Unit) Table 196. SAMEA Live Attenuated Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 197. SAMEA Live Attenuated Vaccines Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 198. SAMEA Live Attenuated Vaccines Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 199. SAMEA Live Attenuated Vaccines Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 200. SAMEA Live Attenuated Vaccines Sales by Country (2021-2026) & (K Units) Table 201. SAMEA Live Attenuated Vaccines Sales by Country (2027-2032) & (K Units) Table 202. SAMEA Live Attenuated Vaccines Sales Price by Country (2021-2026) & (US$/Unit) Table 203. SAMEA Live Attenuated Vaccines Sales Price by Country (2027-2032) & (US$/Unit) Table 204. Brazil Live Attenuated Vaccines Revenue (2021-2032) & (US$ Million) Table 205. Argentina Live Attenuated Vaccines Revenue (2021-2032) & (US$ Million) Table 206. Chile Live Attenuated Vaccines Revenue (2021-2032) & (US$ Million) Table 207. Colombia Live Attenuated Vaccines Revenue (2021-2032) & (US$ Million) Table 208. Peru Live Attenuated Vaccines Revenue (2021-2032) & (US$ Million) Table 209. Saudi Arabia Live Attenuated Vaccines Revenue (2021-2032) & (US$ Million) Table 210. Israel Live Attenuated Vaccines Revenue (2021-2032) & (US$ Million) Table 211. UAE Live Attenuated Vaccines Revenue (2021-2032) & (US$ Million) Table 212. Turkey Live Attenuated Vaccines Revenue (2021-2032) & (US$ Million) Table 213. Iran Live Attenuated Vaccines Revenue (2021-2032) & (US$ Million) Table 214. Egypt Live Attenuated Vaccines Revenue (2021-2032) & (US$ Million) Table 215. Key Raw Materials Table 216. Raw Materials Key Suppliers Table 217. Live Attenuated Vaccines Distributors List Table 218. Live Attenuated Vaccines Customers List Table 219. Research Programs/Design for This Report Table 220. Authors List of This Report Table 221. Secondary Sources Table 222. Primary Sources List of Figures Figure 1. Live Attenuated Vaccines Image Figure 2. Global Live Attenuated Vaccines Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Live Attenuated Vaccines Market Size Share 2021 VS 2025 VS 2032 Figure 4. Bacterial Image Figure 5. Viral Image Figure 6. Global Live Attenuated Vaccines Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Live Attenuated Vaccines Market Size Share 2021 VS 2025 VS 2032 Figure 8. Research Institutes Image Figure 9. Hospitals Image Figure 10. Clinics Image Figure 11. Others Image Figure 12. Global Live Attenuated Vaccines Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Live Attenuated Vaccines Revenue (2021-2032) & (US$ Million) Figure 14. Global Live Attenuated Vaccines Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 15. Global Live Attenuated Vaccines Revenue Market Share by Region: 2025 Versus 2032 Figure 16. Global Live Attenuated Vaccines Revenue Market Share by Region (2021-2032) Figure 17. Global Live Attenuated Vaccines Sales (2021-2032) & (K Units) Figure 18. Global Live Attenuated Vaccines Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 19. Global Live Attenuated Vaccines Sales Market Share by Region (2021-2032) Figure 20. US & Canada & Mexico Live Attenuated Vaccines Sales YoY (2021-2032) & (K Units) Figure 21. Europe Live Attenuated Vaccines Sales YoY (2021-2032) & (K Units) Figure 22. China Live Attenuated Vaccines Sales YoY (2021-2032) & (K Units) Figure 23. Asia (Excluding China) Live Attenuated Vaccines Sales YoY (2021-2032) & (K Units) Figure 24. South America, Middle East and Africa Live Attenuated Vaccines Sales YoY (2021-2032) & (K Units) Figure 25. Global Live Attenuated Vaccines Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 26. Global Live Attenuated Vaccines Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 27. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 28. Global Live Attenuated Vaccines Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Live Attenuated Vaccines Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 30. Global Live Attenuated Vaccines Revenue Market Share by Type (2021-2032) Figure 31. Global Live Attenuated Vaccines Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 32. Global Live Attenuated Vaccines Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Live Attenuated Vaccines Sales Market Share by Type (2021-2032) Figure 34. Global Live Attenuated Vaccines Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 35. Global Live Attenuated Vaccines Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 36. Global Live Attenuated Vaccines Revenue Market Share by Application (2021-2032) Figure 37. Global Live Attenuated Vaccines Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 38. Global Live Attenuated Vaccines Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Live Attenuated Vaccines Sales Market Share by Application (2021-2032) Figure 40. North America Live Attenuated Vaccines Revenue Share by Type (2021-2032) Figure 41. North America Live Attenuated Vaccines Sales Share by Type (2021-2032) Figure 42. North America Live Attenuated Vaccines Revenue Share by Application (2021-2032) Figure 43. North America Live Attenuated Vaccines Sales Share by Application (2021-2032) Figure 44. North America Live Attenuated Vaccines Revenue Share by Country (2021-2032) Figure 45. North America Live Attenuated Vaccines Sales Share by Country (2021-2032) Figure 46. Europe Live Attenuated Vaccines Revenue Share by Type (2021-2032) Figure 47. Europe Live Attenuated Vaccines Sales Share by Type (2021-2032) Figure 48. Europe Live Attenuated Vaccines Revenue Share by Application (2021-2032) Figure 49. Europe Live Attenuated Vaccines Sales Share by Application (2021-2032) Figure 50. Europe Live Attenuated Vaccines Revenue Share by Country (2021-2032) Figure 51. Europe Live Attenuated Vaccines Sales Share by Country (2021-2032) Figure 52. China Live Attenuated Vaccines Revenue Share by Type (2021-2032) Figure 53. China Live Attenuated Vaccines Sales Share by Type (2021-2032) Figure 54. China Live Attenuated Vaccines Revenue Share by Application (2021-2032) Figure 55. China Live Attenuated Vaccines Sales Share by Application (2021-2032) Figure 56. Asia Live Attenuated Vaccines Revenue Share by Type (2021-2032) Figure 57. Asia Live Attenuated Vaccines Sales Share by Type (2021-2032) Figure 58. Asia Live Attenuated Vaccines Revenue Share by Application (2021-2032) Figure 59. Asia Live Attenuated Vaccines Sales Share by Application (2021-2032) Figure 60. Asia Live Attenuated Vaccines Revenue Share by Country (2021-2032) Figure 61. Asia Live Attenuated Vaccines Sales Share by Country (2021-2032) Figure 62. SAMEA Live Attenuated Vaccines Revenue Share by Type (2021-2032) Figure 63. SAMEA Live Attenuated Vaccines Sales Share by Type (2021-2032) Figure 64. SAMEA Live Attenuated Vaccines Revenue Share by Application (2021-2032) Figure 65. SAMEA Live Attenuated Vaccines Sales Share by Application (2021-2032) Figure 66. SAMEA Live Attenuated Vaccines Revenue Share by Country (2021-2032) Figure 67. SAMEA Live Attenuated Vaccines Sales Share by Country (2021-2032) Figure 68. Live Attenuated Vaccines Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Live Attenuated Vaccines Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Bacterial
  • Viral
Applications
  • Research Institutes
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Astellas Pharma
  • CSL
  • Serum Institute Of India
  • GlaxoSmithKline
  • Pfizer
  • Merck
  • Johnson & Johnson
  • Sanofi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Live Attenuated Vaccines Market by Type
  3. 1.2.1 Global Live Attenuated Vaccines Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Bacterial
  5. 1.2.3 Viral
  6. 1.3 Live Attenuated Vaccines Market by Application
  7. 1.3.1 Global Live Attenuated Vaccines Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Research Institutes
  9. 1.3.3 Hospitals
  10. 1.3.4 Clinics
  11. 1.3.5 Others
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Live Attenuated Vaccines Market Dynamics
  1. 2.1 Live Attenuated Vaccines Industry Trends
  2. 2.2 Live Attenuated Vaccines Industry Drivers
  3. 2.3 Live Attenuated Vaccines Industry Opportunities and Challenges
  4. 2.4 Live Attenuated Vaccines Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Live Attenuated Vaccines Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Live Attenuated Vaccines Revenue by Region
  3. 3.2.1 Global Live Attenuated Vaccines Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Live Attenuated Vaccines Revenue by Region (2021-2026)
  5. 3.2.3 Global Live Attenuated Vaccines Revenue by Region (2027-2032)
  6. 3.2.4 Global Live Attenuated Vaccines Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Live Attenuated Vaccines Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Live Attenuated Vaccines Sales by Region
  9. 3.4.1 Global Live Attenuated Vaccines Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Live Attenuated Vaccines Sales by Region (2021-2026)
  11. 3.4.3 Global Live Attenuated Vaccines Sales by Region (2027-2032)
  12. 3.4.4 Global Live Attenuated Vaccines Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Live Attenuated Vaccines Revenue by Manufacturers
  2. 4.1.1 Global Live Attenuated Vaccines Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Live Attenuated Vaccines Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Live Attenuated Vaccines Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Live Attenuated Vaccines Sales by Manufacturers
  6. 4.2.1 Global Live Attenuated Vaccines Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Live Attenuated Vaccines Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Live Attenuated Vaccines Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Live Attenuated Vaccines Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Live Attenuated Vaccines Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Live Attenuated Vaccines Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Live Attenuated Vaccines Manufacturers, Product Type & Application
  13. 4.7 Global Live Attenuated Vaccines Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Live Attenuated Vaccines Market CR5 and HHI
  16. 4.8.2 2025 Live Attenuated Vaccines Tier 1, Tier 2, and Tier 3
5 Live Attenuated Vaccines Market by Type
  1. 5.1 Global Live Attenuated Vaccines Revenue by Type
  2. 5.1.1 Global Live Attenuated Vaccines Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Live Attenuated Vaccines Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Live Attenuated Vaccines Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Live Attenuated Vaccines Sales by Type
  6. 5.2.1 Global Live Attenuated Vaccines Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Live Attenuated Vaccines Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Live Attenuated Vaccines Sales Market Share by Type (2021-2032)
  9. 5.3 Global Live Attenuated Vaccines Price by Type
6 Live Attenuated Vaccines Market by Application
  1. 6.1 Global Live Attenuated Vaccines Revenue by Application
  2. 6.1.1 Global Live Attenuated Vaccines Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Live Attenuated Vaccines Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Live Attenuated Vaccines Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Live Attenuated Vaccines Sales by Application
  6. 6.2.1 Global Live Attenuated Vaccines Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Live Attenuated Vaccines Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Live Attenuated Vaccines Sales Market Share by Application (2021-2032)
  9. 6.3 Global Live Attenuated Vaccines Price by Application
7 Company Profiles
  1. 7.1 Astellas Pharma
  2. 7.1.1 Astellas Pharma Company Information
  3. 7.1.2 Astellas Pharma Business Overview
  4. 7.1.3 Astellas Pharma Live Attenuated Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Astellas Pharma Live Attenuated Vaccines Product Portfolio
  6. 7.1.5 Astellas Pharma Recent Developments
  7. 7.2 CSL
  8. 7.2.1 CSL Company Information
  9. 7.2.2 CSL Business Overview
  10. 7.2.3 CSL Live Attenuated Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 CSL Live Attenuated Vaccines Product Portfolio
  12. 7.2.5 CSL Recent Developments
  13. 7.3 Serum Institute Of India
  14. 7.3.1 Serum Institute Of India Company Information
  15. 7.3.2 Serum Institute Of India Business Overview
  16. 7.3.3 Serum Institute Of India Live Attenuated Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Serum Institute Of India Live Attenuated Vaccines Product Portfolio
  18. 7.3.5 Serum Institute Of India Recent Developments
  19. 7.4 GlaxoSmithKline
  20. 7.4.1 GlaxoSmithKline Company Information
  21. 7.4.2 GlaxoSmithKline Business Overview
  22. 7.4.3 GlaxoSmithKline Live Attenuated Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 GlaxoSmithKline Live Attenuated Vaccines Product Portfolio
  24. 7.4.5 GlaxoSmithKline Recent Developments
  25. 7.5 Pfizer
  26. 7.5.1 Pfizer Company Information
  27. 7.5.2 Pfizer Business Overview
  28. 7.5.3 Pfizer Live Attenuated Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Pfizer Live Attenuated Vaccines Product Portfolio
  30. 7.5.5 Pfizer Recent Developments
  31. 7.6 Merck
  32. 7.6.1 Merck Company Information
  33. 7.6.2 Merck Business Overview
  34. 7.6.3 Merck Live Attenuated Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Merck Live Attenuated Vaccines Product Portfolio
  36. 7.6.5 Merck Recent Developments
  37. 7.7 Johnson & Johnson
  38. 7.7.1 Johnson & Johnson Company Information
  39. 7.7.2 Johnson & Johnson Business Overview
  40. 7.7.3 Johnson & Johnson Live Attenuated Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Johnson & Johnson Live Attenuated Vaccines Product Portfolio
  42. 7.7.5 Johnson & Johnson Recent Developments
  43. 7.8 Sanofi
  44. 7.8.1 Sanofi Company Information
  45. 7.8.2 Sanofi Business Overview
  46. 7.8.3 Sanofi Live Attenuated Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Sanofi Live Attenuated Vaccines Product Portfolio
  48. 7.8.5 Sanofi Recent Developments
8 North America
  1. 8.1 North America Live Attenuated Vaccines Market Size by Type
  2. 8.1.1 North America Live Attenuated Vaccines Revenue by Type (2021-2032)
  3. 8.1.2 North America Live Attenuated Vaccines Sales by Type (2021-2032)
  4. 8.1.3 North America Live Attenuated Vaccines Price by Type (2021-2032)
  5. 8.2 North America Live Attenuated Vaccines Market Size by Application
  6. 8.2.1 North America Live Attenuated Vaccines Revenue by Application (2021-2032)
  7. 8.2.2 North America Live Attenuated Vaccines Sales by Application (2021-2032)
  8. 8.2.3 North America Live Attenuated Vaccines Price by Application (2021-2032)
  9. 8.3 North America Live Attenuated Vaccines Market Size by Country
  10. 8.3.1 North America Live Attenuated Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Live Attenuated Vaccines Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Live Attenuated Vaccines Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Live Attenuated Vaccines Market Size by Type
  2. 9.1.1 Europe Live Attenuated Vaccines Revenue by Type (2021-2032)
  3. 9.1.2 Europe Live Attenuated Vaccines Sales by Type (2021-2032)
  4. 9.1.3 Europe Live Attenuated Vaccines Price by Type (2021-2032)
  5. 9.2 Europe Live Attenuated Vaccines Market Size by Application
  6. 9.2.1 Europe Live Attenuated Vaccines Revenue by Application (2021-2032)
  7. 9.2.2 Europe Live Attenuated Vaccines Sales by Application (2021-2032)
  8. 9.2.3 Europe Live Attenuated Vaccines Price by Application (2021-2032)
  9. 9.3 Europe Live Attenuated Vaccines Market Size by Country
  10. 9.3.1 Europe Live Attenuated Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Live Attenuated Vaccines Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Live Attenuated Vaccines Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
  18. 9.3.9 Nordic Countries
10 China
  1. 10.1 China Live Attenuated Vaccines Market Size by Type
  2. 10.1.1 China Live Attenuated Vaccines Revenue by Type (2021-2032)
  3. 10.1.2 China Live Attenuated Vaccines Sales by Type (2021-2032)
  4. 10.1.3 China Live Attenuated Vaccines Price by Type (2021-2032)
  5. 10.2 China Live Attenuated Vaccines Market Size by Application
  6. 10.2.1 China Live Attenuated Vaccines Revenue by Application (2021-2032)
  7. 10.2.2 China Live Attenuated Vaccines Sales by Application (2021-2032)
  8. 10.2.3 China Live Attenuated Vaccines Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Live Attenuated Vaccines Market Size by Type
  2. 11.1.1 Asia Live Attenuated Vaccines Revenue by Type (2021-2032)
  3. 11.1.2 Asia Live Attenuated Vaccines Sales by Type (2021-2032)
  4. 11.1.3 Asia Live Attenuated Vaccines Price by Type (2021-2032)
  5. 11.2 Asia Live Attenuated Vaccines Market Size by Application
  6. 11.2.1 Asia Live Attenuated Vaccines Revenue by Application (2021-2032)
  7. 11.2.2 Asia Live Attenuated Vaccines Sales by Application (2021-2032)
  8. 11.2.3 Asia Live Attenuated Vaccines Price by Application (2021-2032)
  9. 11.3 Asia Live Attenuated Vaccines Market Size by Country
  10. 11.3.1 Asia Live Attenuated Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Live Attenuated Vaccines Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Live Attenuated Vaccines Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Live Attenuated Vaccines Market Size by Type
  2. 12.1.1 SAMEA Live Attenuated Vaccines Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Live Attenuated Vaccines Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Live Attenuated Vaccines Price by Type (2021-2032)
  5. 12.2 SAMEA Live Attenuated Vaccines Market Size by Application
  6. 12.2.1 SAMEA Live Attenuated Vaccines Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Live Attenuated Vaccines Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Live Attenuated Vaccines Price by Application (2021-2032)
  9. 12.3 SAMEA Live Attenuated Vaccines Market Size by Country
  10. 12.3.1 SAMEA Live Attenuated Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Live Attenuated Vaccines Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Live Attenuated Vaccines Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Live Attenuated Vaccines Value Chain Analysis
  2. 13.1.1 Live Attenuated Vaccines Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Live Attenuated Vaccines Production Mode & Process
  6. 13.2 Live Attenuated Vaccines Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Live Attenuated Vaccines Distributors
  9. 13.2.3 Live Attenuated Vaccines Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst